Company intelligence / Profile preview

OptMed

New York City, New York, United Statesoptmed.com ↗

Ownership: Private
Employees: ~3
Development stage: Commercial

Overview

OptMed has received FDA 510(k) clearance for its TearRepair™ Liquid Skin Protectant, a rapid-drying, methylidene malonate-based liquid barrier film. The company is commercializing this product while also developing additional medical adhesives for both external and potential internal applications. Their proprietary platform offers customizable chemistry with strong biocompatibility and flexibility advantages over existing products[1][3][4].

Therapeutic areas: PulmonologyDermatology
Modalities: DevicePolymer-drug conjugate therapy (for adhesives and protectants)
Industry: Consumable Medical Devices

Drug pipeline

3 assets

BondEase

Commercial

Indications: Wound closure

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on OptMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OptMed.

Explore the full profile